Healthcare - Biotechnology - NASDAQ - US
$ 0.91
-9 %
$ 71.2 M
Market Cap
6.07
P/E
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.[ Read More ]
The intrinsic value of one CTMX stock under the base case scenario is HIDDEN Compared to the current market price of 0.91 USD, CytomX Therapeutics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CTMX
FINANCIALS
101 M
REVENUE
-6.48 M
OPERATING INCOME
-569 K
NET INCOME
-56 M
OPERATING CASH FLOW
-151 M
INVESTING CASH FLOW
30.2 M
FINANCING CASH FLOW
33.4 M
REVENUE
4.11 M
OPERATING INCOME
5.74 M
NET INCOME
-20.7 M
OPERATING CASH FLOW
18.2 M
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
CytomX Therapeutics, Inc.
| Current Assets | 183 M |
| Cash & Short-Term Investments | 175 M |
| Receivables | 3.43 M |
| Other Current Assets | 5 M |
| Non-Current Assets | 18.9 M |
| Long-Term Investments | 0 |
| PP&E | 16.2 M |
| Other Non-Current Assets | 2.68 M |
| Current Liabilities | 156 M |
| Accounts Payable | 1.46 M |
| Short-Term Debt | 9.18 M |
| Other Current Liabilities | 145 M |
| Non-Current Liabilities | 93.3 M |
| Long-Term Debt | 18.8 M |
| Other Non-Current Liabilities | 74.6 M |
EFFICIENCY
Earnings Waterfall
CytomX Therapeutics, Inc.
| Revenue | 101 M |
| Cost Of Revenue | 2.18 M |
| Gross Profit | 99 M |
| Operating Expenses | 108 M |
| Operating Income | -6.48 M |
| Other Expenses | -5.92 M |
| Net Income | -569 K |
RATIOS
97.85%
GROSS MARGIN
-6.41%
OPERATING MARGIN
-0.56%
NET MARGIN
1.20%
ROE
-0.28%
ROA
-3.32%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CytomX Therapeutics, Inc.
| Net Income | -569 K |
| Depreciation & Amortization | 2.18 M |
| Capital Expenditures | -840 K |
| Stock-Based Compensation | 8.56 M |
| Change in Working Capital | -62.5 M |
| Others | -97.3 M |
| Free Cash Flow | -56.9 M |
Wall Street Analysts Price Targets
CytomX Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for CTMX of $4.37 , with forecasts ranging from a low of $2.5 to a high of $8 .
CTMX Lowest Price Target
Wall Street Target
2.5 USD
174.73%
CTMX Average Price Target
Wall Street Target
4.37 USD
380.22%
CTMX Highest Price Target
Wall Street Target
8 USD
779.12%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
CytomX Therapeutics, Inc.
Sold
0-3 MONTHS
34.9 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
99.7 K USD 5
9-12 MONTHS
38.3 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Aug 20, 2024
|
Sell 5.14 K USD
|
Landau Jeffrey B
Chief Business Officer |
- 4181
|
1.2291 USD |
|
2 months ago
Aug 20, 2024
|
Sell 5.14 K USD
|
BELVIN MARCIA
SVP, Chief Scientific Officer |
- 4181
|
1.2291 USD |
|
2 months ago
Aug 20, 2024
|
Sell 5.14 K USD
|
ROWLAND LLOYD A
General Counsel |
- 4181
|
1.2291 USD |
|
2 months ago
Aug 20, 2024
|
Sell 2.44 K USD
|
Ogden Christopher
Chief Financial Officer |
- 1984
|
1.2291 USD |
|
2 months ago
Aug 20, 2024
|
Sell 17.1 K USD
|
McCarthy Sean A.
CEO |
- 13898
|
1.2291 USD |
|
7 months ago
Mar 19, 2024
|
Sell 11 K USD
|
ROWLAND LLOYD A
General Counsel |
- 5268
|
2.0855 USD |
|
7 months ago
Mar 19, 2024
|
Sell 42.2 K USD
|
McCarthy Sean A.
CEO |
- 20223
|
2.0855 USD |
|
7 months ago
Mar 19, 2024
|
Sell 6.2 K USD
|
Ogden Christopher
SVP, Finance and Accounting |
- 2971
|
2.0855 USD |
|
7 months ago
Mar 19, 2024
|
Sell 26.7 K USD
|
BELVIN MARCIA
SVP, Chief Scientific Officer |
- 12795
|
2.0855 USD |
|
7 months ago
Mar 19, 2024
|
Sell 13.7 K USD
|
Landau Jeffrey B
Chief Business Officer |
- 6562
|
2.0855 USD |
|
10 months ago
Dec 20, 2023
|
Sell 18.7 K USD
|
McCarthy Sean A.
CEO |
- 13551
|
1.3807 USD |
|
10 months ago
Dec 20, 2023
|
Sell 5.63 K USD
|
BELVIN MARCIA
SVP, Chief Scientific Officer |
- 4077
|
1.3805 USD |
|
10 months ago
Dec 20, 2023
|
Sell 5.63 K USD
|
Landau Jeffrey B
Chief Business Officer |
- 4077
|
1.3805 USD |
|
10 months ago
Dec 20, 2023
|
Sell 5.63 K USD
|
ROWLAND LLOYD A
General Counsel |
- 4077
|
1.3807 USD |
|
10 months ago
Dec 20, 2023
|
Sell 2.75 K USD
|
Ogden Christopher
SVP, Finance and Accounting |
- 1990
|
1.3806 USD |
|
1 year ago
Sep 22, 2023
|
Sell 5.36 K USD
|
BELVIN MARCIA
SVP, Chief Scientific Officer |
- 4119
|
1.3003 USD |
|
1 year ago
Sep 22, 2023
|
Sell 5.36 K USD
|
Landau Jeffrey B
Chief Business Officer |
- 4119
|
1.3003 USD |
|
1 year ago
Sep 22, 2023
|
Sell 19 K USD
|
McCarthy Sean A.
CEO |
- 14601
|
1.3004 USD |
|
1 year ago
Sep 22, 2023
|
Sell 7.14 K USD
|
ROWLAND LLOYD A
General Counsel |
- 5486
|
1.3006 USD |
|
1 year ago
Mar 29, 2023
|
Bought 7.75 K USD
|
Jones Elaine V
Director |
+ 5000
|
1.55 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.02 K USD
|
Ogden Christopher
SVP, Finance and Accounting |
- 516
|
1.9793 USD |
|
1 year ago
Mar 16, 2023
|
Sell 13.4 K USD
|
McCarthy Sean A.
CEO |
- 7121
|
1.8805 USD |
|
1 year ago
Mar 16, 2023
|
Sell 3.46 K USD
|
Campoy Carlos
Chief Financial Officer |
- 1748
|
1.9791 USD |
|
1 year ago
Mar 16, 2023
|
Sell 4.03 K USD
|
ROWLAND LLOYD A
General Counsel |
- 2037
|
1.979 USD |
|
1 year ago
Mar 16, 2023
|
Sell 2.92 K USD
|
Landau Jeffrey B
Chief Financial Officer |
- 1477
|
1.9792 USD |
|
1 year ago
Mar 16, 2023
|
Sell 8.42 K USD
|
Peterson Amy C.
EVP, Chief Development Officer |
- 4257
|
1.979 USD |
|
2 years ago
Jul 19, 2022
|
Sell 10.6 K USD
|
Peterson Amy C.
EVP, Chief Development Officer |
- 7463
|
1.422 USD |
|
2 years ago
Jul 19, 2022
|
Sell 5.98 K USD
|
Landau Jeffrey B
Chief Business Officer |
- 4206
|
1.4222 USD |
|
2 years ago
Jul 19, 2022
|
Sell 21.2 K USD
|
McCarthy Sean A.
President and CEO |
- 14911
|
1.4222 USD |
|
2 years ago
Jul 19, 2022
|
Sell 7.97 K USD
|
ROWLAND LLOYD A
General Counsel |
- 5602
|
1.4223 USD |
|
2 years ago
Jul 19, 2022
|
Sell 7.97 K USD
|
HANNAH ALISON L.
Chief Medical Officer |
- 5602
|
1.4219 USD |
|
2 years ago
Jul 19, 2022
|
Sell 5.62 K USD
|
Campoy Carlos
Chief Financial Officer |
- 3949
|
1.4224 USD |
|
3 years ago
Jun 16, 2021
|
Sell 704 K USD
|
McCarthy Sean A.
President and CEO |
- 100000
|
7.0447 USD |
|
3 years ago
Mar 31, 2021
|
Sell 749 K USD
|
McCarthy Sean A.
President and CEO |
- 100000
|
7.4947 USD |
|
4 years ago
May 12, 2020
|
Sell 540 K USD
|
McCarthy Sean A.
President and CEO |
- 36000
|
15 USD |
|
5 years ago
Mar 04, 2019
|
Bought 93 K USD
|
ROWLAND LLOYD A
General Counsel |
+ 9000
|
10.33 USD |
|
5 years ago
Dec 12, 2018
|
Sell 45 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
15 USD |
|
6 years ago
Nov 01, 2018
|
Sell 45 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
15 USD |
|
6 years ago
Nov 01, 2018
|
Sell 1.5 K USD
|
McCarthy Sean A.
President and CEO |
- 100
|
15.005 USD |
|
6 years ago
Nov 02, 2018
|
Sell 17.3 K USD
|
McCarthy Sean A.
President and CEO |
- 1156
|
15.007 USD |
|
6 years ago
Nov 01, 2018
|
Sell 79 K USD
|
McCarthy Sean A.
President and CEO |
- 5270
|
15 USD |
|
6 years ago
Oct 01, 2018
|
Sell 55.4 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
18.46 USD |
|
6 years ago
Sep 04, 2018
|
Sell 67.2 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
22.39 USD |
|
6 years ago
Sep 04, 2018
|
Sell 285 K USD
|
McCarthy Sean A.
President and CEO |
- 13052
|
21.862 USD |
|
6 years ago
Aug 01, 2018
|
Sell 78.2 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
26.05 USD |
|
6 years ago
Jul 05, 2018
|
Sell 113 K USD
|
McCarthy Sean A.
President and CEO |
- 4497
|
25.0586 USD |
|
6 years ago
Jul 03, 2018
|
Sell 50.9 K USD
|
McCarthy Sean A.
President and CEO |
- 2028
|
25.089 USD |
|
6 years ago
Jul 03, 2018
|
Sell 50.9 K USD
|
McCarthy Sean A.
President and CEO |
- 2028
|
25.089 USD |
|
6 years ago
Jul 02, 2018
|
Sell 67.7 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
22.56 USD |
|
6 years ago
Jul 02, 2018
|
Sell 306 K USD
|
McCarthy Sean A.
President and CEO |
- 13052
|
23.4223 USD |
|
6 years ago
Jun 01, 2018
|
Sell 77.8 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
25.931 USD |
|
6 years ago
May 01, 2018
|
Sell 79.6 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
26.5207 USD |
|
6 years ago
May 01, 2018
|
Sell 520 K USD
|
McCarthy Sean A.
President and CEO |
- 19578
|
26.5473 USD |
|
6 years ago
Apr 02, 2018
|
Sell 84.4 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 3000
|
28.12 USD |
|
6 years ago
Mar 26, 2018
|
Sell 160 K USD
|
GLUCK FREDERICK W
Director |
- 5000
|
31.9283 USD |
|
6 years ago
Mar 02, 2018
|
Sell 485 K USD
|
GLUCK FREDERICK W
Director |
- 16181
|
30.0022 USD |
|
6 years ago
Mar 02, 2018
|
Sell 485 K USD
|
HUMPHREY RACHEL
Chief Medical Officer |
- 16160
|
30 USD |
|
6 years ago
Mar 02, 2018
|
Sell 381 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 12541
|
30.411 USD |
|
6 years ago
Mar 02, 2018
|
Sell 166 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 5515
|
30.059 USD |
|
6 years ago
Mar 02, 2018
|
Sell 60.3 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 1944
|
31.015 USD |
|
6 years ago
Mar 01, 2018
|
Sell 382 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 13000
|
29.4032 USD |
|
6 years ago
Mar 01, 2018
|
Sell 576 K USD
|
McCarthy Sean A.
President and CEO |
- 19578
|
29.428 USD |
|
6 years ago
Feb 28, 2018
|
Sell 715 K USD
|
HUMPHREY RACHEL
Chief Medical Officer |
- 23840
|
30 USD |
|
6 years ago
Feb 28, 2018
|
Sell 115 K USD
|
GLUCK FREDERICK W
Director |
- 3819
|
30 USD |
|
6 years ago
Feb 28, 2018
|
Sell 115 K USD
|
GLUCK FREDERICK W
Director |
- 3819
|
30 USD |
|
6 years ago
Feb 01, 2018
|
Sell 68 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2548
|
26.6915 USD |
|
6 years ago
Jan 05, 2018
|
Sell 163 K USD
|
McCarthy Sean A.
President and CEO |
- 6526
|
25.01 USD |
|
6 years ago
Jan 05, 2018
|
Sell 250 K USD
|
GLUCK FREDERICK W
Director |
- 10000
|
25.0078 USD |
|
6 years ago
Jan 02, 2018
|
Sell 275 K USD
|
McCarthy Sean A.
President and CEO |
- 13052
|
21.04 USD |
|
6 years ago
Jan 02, 2018
|
Sell 52.8 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
21.11 USD |
|
6 years ago
Dec 26, 2017
|
Sell 111 K USD
|
GLUCK FREDERICK W
Director |
- 5000
|
22.2851 USD |
|
6 years ago
Dec 01, 2017
|
Sell 51.4 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
20.58 USD |
|
6 years ago
Dec 01, 2017
|
Sell 295 K USD
|
McCarthy Sean A.
President and CEO |
- 14340
|
20.6 USD |
|
7 years ago
Nov 01, 2017
|
Sell 285 K USD
|
McCarthy Sean A.
President and CEO |
- 14342
|
19.86 USD |
|
7 years ago
Nov 01, 2017
|
Sell 50 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
20 USD |
|
7 years ago
Oct 04, 2017
|
Sell 461 K USD
|
McCarthy Sean A.
President and CEO |
- 19120
|
24.13 USD |
|
7 years ago
Oct 04, 2017
|
Sell 1.18 M USD
|
Kavanaugh William Michael
CSO, Head Res.&Non-Clin. Dev. |
- 48368
|
24.34 USD |
|
7 years ago
Oct 04, 2017
|
Sell 243 K USD
|
GLUCK FREDERICK W
Director |
- 10000
|
24.268 USD |
|
7 years ago
Oct 02, 2017
|
Sell 178 K USD
|
McCarthy Sean A.
President and CEO |
- 9562
|
18.57 USD |
|
7 years ago
Oct 04, 2017
|
Sell 603 K USD
|
TEPPER ROBERT I
10 percent owner |
- 24777
|
24.34 USD |
|
7 years ago
Oct 02, 2017
|
Sell 45.2 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
18.1 USD |
|
7 years ago
Sep 26, 2017
|
Sell 86.5 K USD
|
GLUCK FREDERICK W
Director |
- 5000
|
17.2952 USD |
|
7 years ago
Sep 01, 2017
|
Sell 166 K USD
|
McCarthy Sean A.
President and CEO |
- 9562
|
17.32 USD |
|
7 years ago
Sep 01, 2017
|
Sell 6.44 K USD
|
McCarthy Sean A.
President and CEO |
- 368
|
17.5 USD |
|
7 years ago
Aug 31, 2017
|
Sell 115 K USD
|
McCarthy Sean A.
President and CEO |
- 6562
|
17.5 USD |
|
7 years ago
Aug 31, 2017
|
Sell 52.5 K USD
|
McCarthy Sean A.
President and CEO |
- 3000
|
17.51 USD |
|
7 years ago
Aug 31, 2017
|
Sell 161 K USD
|
McCarthy Sean A.
President and CEO |
- 9194
|
17.5 USD |
|
7 years ago
Sep 19, 2017
|
Sell 360 K USD
|
TEPPER ROBERT I
10 percent owner |
- 20000
|
18 USD |
|
7 years ago
Sep 01, 2017
|
Sell 42.9 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
17.17 USD |
|
7 years ago
Sep 01, 2017
|
Sell 172 K USD
|
McCarthy Sean A.
President and CEO |
- 9930
|
17.32 USD |
|
7 years ago
Aug 31, 2017
|
Sell 276 K USD
|
McCarthy Sean A.
President and CEO |
- 15756
|
17.5 USD |
|
7 years ago
Aug 31, 2017
|
Sell 52.5 K USD
|
McCarthy Sean A.
President and CEO |
- 3000
|
17.51 USD |
|
7 years ago
Aug 09, 2017
|
Sell 37.5 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
15 USD |
|
7 years ago
Aug 09, 2017
|
Sell 71.7 K USD
|
McCarthy Sean A.
President and CEO |
- 4781
|
15 USD |
|
7 years ago
Jul 03, 2017
|
Sell 74.2 K USD
|
McCarthy Sean A.
President and CEO |
- 4781
|
15.52 USD |
|
7 years ago
Jul 03, 2017
|
Sell 38.7 K USD
|
RAY DEBANJAN
Chief Financial Officer |
- 2500
|
15.47 USD |
|
7 years ago
Jun 29, 2017
|
Sell 240 K USD
|
TEPPER ROBERT I
10 percent owner |
- 15000
|
16 USD |
|
7 years ago
Jun 26, 2017
|
Sell 73 K USD
|
GLUCK FREDERICK W
Director |
- 5000
|
14.61 USD |
|
7 years ago
Jun 26, 2017
|
Sell 67.2 K USD
|
McCarthy Sean A.
President and CEO |
- 4481
|
15 USD |
|
7 years ago
Jun 05, 2017
|
Sell 4.5 K USD
|
McCarthy Sean A.
President and CEO |
- 300
|
15 USD |
|
7 years ago
May 01, 2017
|
Sell 75.1 K USD
|
McCarthy Sean A.
President and CEO |
- 4781
|
15.7 USD |
|
7 years ago
Apr 12, 2017
|
Sell 464 K USD
|
STARR KEVIN P
10 percent owner |
- 28357
|
16.3555 USD |
|
7 years ago
Apr 03, 2017
|
Sell 81 K USD
|
McCarthy Sean A.
President and CEO |
- 4781
|
16.94 USD |
|
7 years ago
Apr 04, 2017
|
Sell 83.7 K USD
|
McCarthy Sean A.
President and CEO |
- 4781
|
17.5 USD |
|
7 years ago
Mar 23, 2017
|
Sell 17 M USD
|
THIRD ROCK VENTURES LP
10 percent owner |
- 1000000
|
17.0002 USD |
|
7 years ago
Mar 27, 2017
|
Sell 11.7 M USD
|
THIRD ROCK VENTURES LP
10 percent owner |
- 650000
|
18.0003 USD |
|
7 years ago
Mar 27, 2017
|
Sell 0 USD
|
Exter Neil
Director |
- 0
|
0 USD |
|
7 years ago
Mar 20, 2017
|
Sell 196 K USD
|
Goeltz II Robert C.
Chief Financial Officer |
- 10000
|
19.6 USD |
|
7 years ago
Mar 20, 2017
|
Sell 230 K USD
|
Goeltz II Robert C.
Chief Financial Officer |
- 11517
|
20 USD |
|
7 years ago
Mar 20, 2017
|
Sell 281 K USD
|
McCarthy Sean A.
President and CEO |
- 14343
|
19.6 USD |
|
7 years ago
Mar 03, 2017
|
Sell 215 K USD
|
McCarthy Sean A.
President and CEO |
- 14343
|
15 USD |
|
7 years ago
Nov 29, 2016
|
Sell 247 K USD
|
SHANNON TIMOTHY M
Director |
- 22086
|
11.1839 USD |
|
7 years ago
Nov 29, 2016
|
Sell 247 K USD
|
Canaan IX L.P.
Director |
- 22086
|
11.1839 USD |
|
7 years ago
Nov 23, 2016
|
Sell 129 K USD
|
SHANNON TIMOTHY M
Director |
- 10890
|
11.8385 USD |
|
7 years ago
Nov 25, 2016
|
Sell 79.3 K USD
|
SHANNON TIMOTHY M
Director |
- 6729
|
11.7909 USD |
|
7 years ago
Nov 28, 2016
|
Sell 236 K USD
|
SHANNON TIMOTHY M
Director |
- 20840
|
11.3312 USD |
|
7 years ago
Nov 23, 2016
|
Sell 129 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 10890
|
11.8385 USD |
|
7 years ago
Nov 25, 2016
|
Sell 79.3 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 6729
|
11.7909 USD |
|
7 years ago
Nov 28, 2016
|
Sell 236 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 20840
|
11.3312 USD |
|
7 years ago
Nov 22, 2016
|
Sell 498 K USD
|
SHANNON TIMOTHY M
Director |
- 42550
|
11.7057 USD |
|
7 years ago
Nov 22, 2016
|
Sell 498 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 42550
|
11.7057 USD |
|
8 years ago
Nov 17, 2016
|
Sell 218 K USD
|
SHANNON TIMOTHY M
Director |
- 18971
|
11.5027 USD |
|
8 years ago
Nov 18, 2016
|
Sell 149 K USD
|
SHANNON TIMOTHY M
Director |
- 12805
|
11.6427 USD |
|
7 years ago
Nov 21, 2016
|
Sell 159 K USD
|
SHANNON TIMOTHY M
Director |
- 13548
|
11.7202 USD |
|
8 years ago
Nov 17, 2016
|
Sell 218 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 18971
|
11.5027 USD |
|
8 years ago
Nov 18, 2016
|
Sell 149 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 12805
|
11.6427 USD |
|
7 years ago
Nov 21, 2016
|
Sell 159 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 13548
|
11.7202 USD |
|
8 years ago
Nov 15, 2016
|
Sell 379 K USD
|
SHANNON TIMOTHY M
Director |
- 33064
|
11.477 USD |
|
8 years ago
Nov 16, 2016
|
Sell 214 K USD
|
SHANNON TIMOTHY M
Director |
- 18517
|
11.5544 USD |
|
8 years ago
Nov 15, 2016
|
Sell 379 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 33064
|
11.477 USD |
|
8 years ago
Nov 16, 2016
|
Sell 214 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 18517
|
11.5544 USD |
|
8 years ago
Nov 10, 2016
|
Sell 300 K USD
|
SHANNON TIMOTHY M
Director |
- 27135
|
11.0702 USD |
|
8 years ago
Nov 11, 2016
|
Sell 396 K USD
|
SHANNON TIMOTHY M
Director |
- 35391
|
11.2023 USD |
|
8 years ago
Nov 14, 2016
|
Sell 266 K USD
|
SHANNON TIMOTHY M
Director |
- 23744
|
11.2052 USD |
|
8 years ago
Nov 10, 2016
|
Sell 300 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 27135
|
11.0702 USD |
|
8 years ago
Nov 11, 2016
|
Sell 396 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 35391
|
11.2023 USD |
|
8 years ago
Nov 14, 2016
|
Sell 266 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 23744
|
11.2052 USD |
|
8 years ago
Nov 09, 2016
|
Sell 151 K USD
|
SHANNON TIMOTHY M
Director |
- 13730
|
11.0341 USD |
|
8 years ago
Nov 09, 2016
|
Sell 151 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 13730
|
11.0341 USD |
|
8 years ago
Jun 08, 2016
|
Sell 231 K USD
|
SHANNON TIMOTHY M
Director |
- 22885
|
10.08 USD |
|
8 years ago
Jun 09, 2016
|
Sell 230 K USD
|
SHANNON TIMOTHY M
Director |
- 22842
|
10.06 USD |
|
8 years ago
Jun 10, 2016
|
Sell 27 K USD
|
SHANNON TIMOTHY M
Director |
- 2700
|
10.01 USD |
|
8 years ago
Jun 08, 2016
|
Sell 231 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 22885
|
10.08 USD |
|
8 years ago
Jun 09, 2016
|
Sell 230 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 22842
|
10.06 USD |
|
8 years ago
Jun 10, 2016
|
Sell 27 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 2700
|
10.01 USD |
|
8 years ago
Jun 06, 2016
|
Sell 1.02 M USD
|
SHANNON TIMOTHY M
Director |
- 101767
|
10.01 USD |
|
8 years ago
Jun 07, 2016
|
Sell 97.6 K USD
|
SHANNON TIMOTHY M
Director |
- 9731
|
10.03 USD |
|
8 years ago
Jun 06, 2016
|
Sell 1.02 M USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 101767
|
10.01 USD |
|
8 years ago
Jun 07, 2016
|
Sell 97.6 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 9731
|
10.03 USD |
|
8 years ago
Jun 02, 2016
|
Sell 444 K USD
|
SHANNON TIMOTHY M
Director |
- 41193
|
10.79 USD |
|
8 years ago
Jun 03, 2016
|
Sell 200 K USD
|
SHANNON TIMOTHY M
Director |
- 18428
|
10.83 USD |
|
8 years ago
Jun 02, 2016
|
Sell 444 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 41193
|
10.79 USD |
|
8 years ago
Jun 03, 2016
|
Sell 200 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 18428
|
10.83 USD |
|
8 years ago
Jun 01, 2016
|
Sell 241 K USD
|
SHANNON TIMOTHY M
Director |
- 22463
|
10.75 USD |
|
8 years ago
Jun 01, 2016
|
Sell 241 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 22463
|
10.75 USD |
|
8 years ago
May 27, 2016
|
Sell 266 K USD
|
SHANNON TIMOTHY M
Director |
- 25082
|
10.6 USD |
|
8 years ago
May 27, 2016
|
Sell 266 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 25082
|
10.6 USD |
|
8 years ago
May 25, 2016
|
Sell 115 K USD
|
SHANNON TIMOTHY M
Director |
- 11456
|
10.02 USD |
|
8 years ago
May 26, 2016
|
Sell 416 K USD
|
SHANNON TIMOTHY M
Director |
- 39887
|
10.43 USD |
|
8 years ago
May 25, 2016
|
Sell 115 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 11456
|
10.02 USD |
|
8 years ago
May 26, 2016
|
Sell 416 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 39887
|
10.43 USD |
|
8 years ago
May 23, 2016
|
Sell 122 K USD
|
SHANNON TIMOTHY M
Director |
- 12053
|
10.1 USD |
|
8 years ago
May 24, 2016
|
Sell 12 K USD
|
SHANNON TIMOTHY M
Director |
- 1200
|
10 USD |
|
8 years ago
May 23, 2016
|
Sell 122 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 12053
|
10.1 USD |
|
8 years ago
May 24, 2016
|
Sell 12 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 1200
|
10 USD |
|
8 years ago
May 19, 2016
|
Sell 25.4 K USD
|
SHANNON TIMOTHY M
Director |
- 2500
|
10.14 USD |
|
8 years ago
May 20, 2016
|
Sell 62.4 K USD
|
SHANNON TIMOTHY M
Director |
- 6187
|
10.09 USD |
|
8 years ago
May 19, 2016
|
Sell 25.4 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 2500
|
10.14 USD |
|
8 years ago
May 20, 2016
|
Sell 62.4 K USD
|
Canaan IX L.P.
director, 10 percent owner: |
- 6187
|
10.09 USD |
7. News
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P.
seekingalpha.com
- 1 week ago
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year ago.
zacks.com
- 1 week ago
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -
globenewswire.com
- 1 week ago
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.
globenewswire.com
- 2 months ago
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -
globenewswire.com
- 3 months ago
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
globenewswire.com
- 4 months ago
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
globenewswire.com
- 5 months ago
Buy Alert: 3 Penny Stocks That Will Explode in 2024
When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.
investorplace.com
- 5 months ago
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.
investorplace.com
- 5 months ago
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.
globenewswire.com
- 5 months ago
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.
globenewswire.com
- 6 months ago
Why Is CytomX (CTMX) Stock Down 43% Today?
CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904.
investorplace.com
- 6 months ago
8. Profile Summary
CytomX Therapeutics, Inc. CTMX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 71.2 M
Dividend Yield
0.00%
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Contact
151 Oyster Point Boulevard, South San Francisco, CA, 94080
https://www.cytomx.com
IPO Date
Oct. 8, 2015
Employees
120
Officers
Dr. Sean A. McCarthy DPHIL
Chairman & Chief Executive Officer
Dr. Hoyoung Huh M.D., Ph.D.
Special Advisor to Chief Executive Officer
Mr. Jeffrey Landau B.S., M.B.A.
Senior Vice President, Head of Strategy & Chief Business Officer
Ms. Dawn Benson
Senior Vice President of Quality & Product Manufacturing
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
Mr. Christopher W. Ogden
Chief Financial Officer
Mr. Lloyd A. Rowland Jr., J.D.
Senior Vice President, General Counsel, Chief Compliance Officer & Secretary
Ms. Danielle Olander-Moghadassian
Senior Vice President & Chief Human Resources Officer
Dr. Marcia P. Belvin Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Leslie Robbins
Senior Vice President of Intellectual Property